Researchers aren't exactly clear why the drug appears to work better in people with overweight or obesity (but not diabetes) compared to people with diabetes who also have overweight or obesity
For consumers researching their options, understanding the regulatory status, pricing structures, format differences, and access pathways across these categories helps inform medical decisions made in consultation with healthcare providers
FDA approval of exenatide, its first generic injectable GLP-1 agonist, Amneal (2024) Teva announces FDA approval and launch of generic Saxenda (liraglutide injection) first generic GLP-1 indicated for weight loss, Teva Pharmaceuticals (2025) Exenatide, DailyMed (2025) Byetta, DailyMed (2025) Liraglutide (generic Victoza), DailyMed (2025) Liraglutide (generic Saxenda), DailyMed (2025) Victoza, DailyMed (2025) Saxenda, DailyMed (2025) Compounding and the FDA: Questions and answers, U.S
doi:10.1038/srep12044
All products supplied by UKPEPSHOP are handled to a high quality standard suitable for research applications
